
Obicetrapib Plus Ezetimibe Reduced LDL-C in Patients With or at Risk of Atherosclerotic Cardiovascular Disease
The fixed-dose combination (FDC) of obicetrapib (NewAmsterdam Pharma) plus ezetimibe (Zetia; Merck and Schering-Plough Pharmaceuticals) significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with pre-existing or at high risk for …